Precision-engineered Nanoparticles for Enhanced Drug Delivery

Bao Miao^*
*Correspondence: Bao Miao, Department of Haematology, University of Electronic Science and Technology of China, Si Chuan Sheng, China, Email:

Introduction

The field of medicine is experiencing a paradigm shift with the advent of nanotechnology, particularly in the realm of drug delivery systems. Precisionengineered nanoparticles have emerged as a revolutionary tool for enhancing the efficacy and specificity of therapeutics. These nanoparticles, designed at the molecular level, possess unique physicochemical properties, such as high surface area-to-volume ratio, biocompatibility, and tunable functionality, making them ideal carriers for drugs. By enabling targeted delivery to specific tissues or cells, nanoparticles minimize systemic side effects, reduce drug wastage, and improve therapeutic outcomes. From cancer treatment to infectious disease management, nanoparticles are unlocking new possibilities for overcoming longstanding challenges in medicine. Traditional drug delivery methods often suffer from limitations such as poor bioavailability, rapid degradation, and non-specific distribution, which can compromise the efficacy of treatment. Nanoparticles address these issues by providing controlled release mechanisms, enhanced cellular uptake, and the ability to cross biological barriers. In addition, their versatility allows for customization with surface ligands, enabling active targeting of diseased cells while sparing healthy tissues. This transformative approach is reshaping the pharmaceutical landscape, offering hope for tackling complex diseases with greater precision and fewer side effects. As research in nanomedicine progresses, precisionengineered nanoparticles are set to play an even greater role in the future of healthcare, bridging the gap between scientific innovation and clinical application.

Description

Due to liver accumulation, although lipid nanoparticles (LNPs) are a clinically mature technology for the delivery of genetic medicines, their therapeutic applications are limited. By allowing the delivery of messenger RNA (mRNA) and gene editing systems to non-liver tissues, our group has recently developed selective organ targeting (SORT) nanoparticles that expand the therapeutic applications of genetic medicines. We investigated the mechanistic factors that define SORT nanoparticles' organ-targeting properties in order to comprehend how they overcome the delivery barrier of liver hepatocyte accumulation [1]. We found that the compound idea of the additional SORT atom controlled biodistribution, worldwide/obvious pKa and serum protein associations of SORT nanoparticles. In addition, we provide evidence for an endogenous targeting mechanism that involves 1) the desorption of poly(ethylene glycol) lipids from the surface of the LNP,) the binding of distinct proteins to the surface of the nanoparticle as a result of recognition of exposed SORT molecules) interactions between surfacebound proteins and cognate receptors that are highly expressed in particular tissues. These results suggest that the recruitment of specific proteins to a nanoparticle's surface can enable drug delivery beyond the liver, establishing a crucial link between the molecular composition of SORT nanoparticles and their unique and precise organ-targeting properties [2].

New approaches to gene targeting based on RNA oligonucleotides were developed following the discovery of RNA interference (RNAi). Mammalian cells' endogenous RNAi machinery has been extensively studied in recent years, resulting in the discovery of molecular mechanisms that enable precise dsRNA-mediated gene expression regulation. These RNA duplexes are delivered from a stem-circle structure called the forerunner miRNA and are handled into short dsRNAs by Dicer [3,4]. Because of the short acknowledgment length necessity, an individual miRNA can tie to numerous mRNAs and thus it can direct various qualities because of decreased restricting particularity. When compared to siRNAs, this also results in less effective gene silencing for any given gene. In contrast, shRNAs are engineered as plasmids in the laboratory. The plasmid is used to express RNA molecules with a tight hairpin turn, making it easier to use RNAi to silence target genes over time. Therefore, intra-cellular delivery of a plasmid containing specific shRNA sequences, capable of targeting mRNA strands after Dicer processing, is typically required for shRNA expression in cells. Because they are based on DNA, shRNA plasmids outperform dsRNAs in terms of resistance to degradation. However, additional transcriptional steps are required prior to the generation of dsRNA because shRNAs necessitate the use of an expression vector.

The behavior of mucus in the lungs is also altered by disease. High levels of MUC5AC and MUC5B polymers characterize lung mucus, a barrier that significantly affects NPs inhaled 118,157. However, because cystic fibrosis mucus has a higher viscosity, which encourages biofilm formation by entrapping pathogens and limiting neutrophil mobility157,158, increased MUC5B expression and excessive cross-linking of polymers in the mucus results in decreased pore size and low rates of mucus clearance [5].

Conclusion

Precision-engineered nanoparticles represent a groundbreaking advancement in drug delivery, offering unparalleled opportunities to revolutionize how medicines are administered and their effectiveness enhanced. Their ability to target specific cells or tissues, improve bioavailability, and minimize adverse effects marks a significant step forward in personalized medicine. By overcoming the limitations of conventional drug delivery methods, nanoparticles are not only enhancing the efficacy of existing therapeutics but also enabling the development of new treatments for complex and previously untreatable diseases. The potential applications of these nanoparticles extend beyond improving individual patient outcomes; they also hold promise for reducing healthcare costs by streamlining treatment protocols and increasing the efficiency of drug formulations. However, the widespread adoption of nanoparticle-based drug delivery systems requires addressing challenges such as scalability, regulatory compliance, and ensuring long-term safety and efficacy. Ongoing research and interdisciplinary collaboration will be key to unlocking the full potential of this technology. As we stand at the cusp of a nanotechnology-driven era in medicine, precision-engineered nanoparticles are paving the way for transformative breakthroughs. By combining innovation with clinical need, they offer a powerful tool to enhance the quality of life for patients worldwide, reinforcing the critical role of nanomedicine in shaping the future of healthcare.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Wang, Jianxin, Andrea M. Potocny, Joel Rosenthal and Emily S. Day, et al. "Gold nanoshell-linear tetrapyrrole conjugates for near infrared-activated dual photodynamic and photothermal therapies." ACS Omega 5 (2019): 926-940.

Google Scholar, Crossref, Indexed at

2. Bobo, Daniel, Kye J. Robinson, Jiaul Islam and Kristofer J. Thurecht, et al. "Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date." Pharma Res 33 (2016): 2373-2387.

Google Scholar, Crossref, Indexed at

3. Arias, Laís Salomão, Juliano Pelim Pessan, Ana Paula Miranda Vieira and Taynara Maria Toito de Lima, et al. "Iron oxide nanoparticles for biomedical applications: A perspective on synthesis, drugs, antimicrobial activity and toxicity." Antibiotics 7 (2018): 46. 

Google Scholar, Crossref, Indexed at

4. Huang, Kuan-Wei, Fu-Fei Hsu, Jiantai Timothy Qiu and Guann-Jen Chern, et al. "Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer." Sci Adv 6 (2020): eaax5032.

Google Scholar, Crossref, Indexed at

5. Xu, Cheng, Jutaek Nam, Hao Hong and Yao Xu, et al. "Positron emission tomography-guided photodynamic therapy with biodegradable mesoporous silica nanoparticles for personalized cancer immunotherapy." ACS Nano 13 (2019): 12148-12161.

Google Scholar, Crossref, Indexed at